Encorafenib and Binimetinib in Combination With Targeted Third Agents in Advanced BRAF Melanoma (LOGIC-2)
The LOGIC 2 Trial a Phase II, Multi-Center, Open-Label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma
Category & Conditions: Cancer
Medicine: Braftovi (encorafinib) + Mektovi (binimetinib)
ClinicalTrials.gov Identifier (NCT): NCT02159066
Protocol ID: C4221013
PrintDownloadOpen Plain Language Summary Result: Click here